Changes

Jump to: navigation, search

Oral Diabetes Drugs

2,671 bytes removed, 10:28, 16 October 2007
/* Product pipeline */
===Product pipeline===
 
[[Image:Roche.jpg|thumb|center|600px|]]
{|border="2" cellspacing="0" cellpadding="4" width="100%"
|align = "center" bgcolor = "#FFFF99" colspan = "3" |<font size = "4">'''Product Pipeline'''</font>
|align = "center"|Gastrin <nowiki>+</nowiki> DPP IV Inhibitor
|align = "center"|<font color="#0000FF"><u>[http://www.transitiontherapeutics.com/technology/index.php Transition Therapeutics]</u></font>
|align = "center"|2Preclinical
|-
|-
|colspan = "3"|<font color="#FF6600">'''Insulin sensitizer'''</font>
 
|-
|align = "center"|MBX 102
|align = "center"|<font color="#0000FF"><u>[http://www.medicalnewstoday.com/articles/26017.php Metabolex]</u></font>
|align = "center"|2
 
|-
|align = "center"|MBX-2044
|align = "center"|<font color="#0000FF"><u>[http://www.metabolex.com/pipeline.html Metabolex]</u></font>
|align = "center"|1
|-
|-
|align = "center"|NCX 4016(Nitric Oxide donating derivative of Acetyl Salicylic acid)
|align = "center"|<font color="#0000FF"><u>[http://www.nicox.com/update/NCX_4016.html NicOx]</u></font>
|align = "center"|2
 
|-
|align = "center"|Cholebine
|align = "center"|<font color="#0000FF"><u>[http://www.m-pharma.co.jp/cgi-bin/pageview.cgi?pass=/e/develop/situation.html Mitsubishi Pharma]</u></font>
|align = "center"|2
|-
|align = "center"|NovoNorm®(repaglinide)/Metformin
|align = "center"|<font color="#0000FF"><u>[http://www.novonordisk.com/science/pipeline/rd_pipeline.asp?showid=6 Novo Nordisk]</u></font>
|align = "center"|3
|-
|colspan = "3"|<font color="#FF6600">'''GLP 1 Analogue / AgonistsBiguanides'''</font>|-|-
|-
|align = "center"|Gastrin <nowiki>+</nowiki> Metformin
|align = "center"|<font color="#0000FF"><u>[http://www.transitiontherapeutics.com/technology/index.php Transition Therapeutics]</u></font>
|align = "center"|1
 
|-
|colspan = "3"|<font color="#FF6600">'''GLP 1 Analogue / Agonists'''</font> GLP 1 Analogues have to be injected subcutaneously, Emisphere is working on an oral analogue
 
|-
|align = "center"|Abiglutide (716155)
|align = "center"|<font color="#0000FF"><u>[http://www.gsk.com/investors/product_pipeline/docs/pipeline.pdf glaxosmithkline]</u></font>
|align = "center"|2
|-
|align = "center"|TH0318
|-
|colspan = "3"|<font color="#FF6600">'''Peroxisome Proliferator-Activated Receptor (PPAR) agonist/analogue'''</font>
 
|-
|align = "center"|CS-011 (Rivoglitazone)
|align = "center"|Sankyo
|align = "center"|2
 
|-
|align = "center"|Metaglidasen(MBX 102)
|align = "center"|<font color="#0000FF"><u>[http://www.medicalnewstoday.com/articles/26017.php Metabolex]</u></font>
|align = "center"|2
 
|-
|align = "center"|MBX-2044
|align = "center"|<font color="#0000FF"><u>[http://www.metabolex.com/pipeline.html Metabolex]</u></font>
|align = "center"|1
|-
|align = "center"|<font color="#0000FF"><u>[http://www.drugs.com/nda/muraglitazar_041223.html Bristol-Myers Squibb ]</u></font>
|align = "center"|3
 
|-
|align = "center"|R483
|align = "center"|<font color="#0000FF"><u>[http://www.roche.com/pages/downloads/investor/pdf/praesentations/irp050504rdd14.pdf Roche]</u></font>
|align = "center"|2
 
|-
|align = "center"|PPM-204
|align = "center"|<font color="#0000FF"><u>[http://www.wyeth.com/research/pipeline Wyeth]</u>, <u>[http://www.invitrogen.com/downloads/Discovery_Inhibitor_Oncogenic_B-RAF.pdf Plexxikon]</u></font>
|align = "center"|2
 
|-
|align = "center"|<font color="#0000FF"><u>[http://www.osip.com/PSN010 OSI]</u></font>
|align = "center"|&nbsp;
 
|-
|colspan = "3"|<font color="#FF6600">'''β3-Adrenergic Receptor Agonist'''</font>
 
|-
|align = "center"|Solabegron (GW427353)
|align = "center"|<font color="#0000FF"><u>[http://clinicaltrials.gov/ct/gui/show/NCT00401479?order=1 Glaxosmithkline]</u></font>
|align = "center"|1
|-
|align = "center"|<font color="#0000FF"><u>[http://www.isispharm.com/product_pipeline.html Isis]</u></font>
|align = "center"|1
 
|-
|colspan = "3"|<font color="#FF6600">'''Antisense drug for Glucocorticoid Receptor (GCCR)'''</font>
|-
|-
|align = "center"|189075
|align = "center"|<font color="#0000FF"><u>[http://clinicaltrialswww.govgsk.com/ctinvestors/guiproduct_pipeline/showdocs/NCT00401479?order=1 pipeline.pdf Glaxosmithkline]</u></font>
|align = "center"|2
|-
|colspan align = "3center"|869682|align = "center"|<font color="#FF66000000FF">'''N-methyl-D-aspartic acid (NMDA) receptor antagonist'''<u>[http://www.gsk.com/investors/product_pipeline/docs/pipeline.pdf Glaxosmithkline]</u></font> |-|align = "center"|Perzinfotel|align = "center"|Wyeth
|align = "center"|2
|align = "center"|<font color="#0000FF"><u>[http://www.theratech.com/en/products-therapeutic-peptides/pipeline.php Theratechnolgies]</u></font>
|align = "center"|&nbsp;
 
|-
|colspan = "3"|<font color="#FF6600">'''Aldolase reductase inhibitor'''</font>
 
|-
|align = "center"|SNK-860, fidarestat
|align = "center"|<font color="#0000FF"><u>[http://care.diabetesjournals.org/cgi/reprint/24/10/1776.pdf Sankyo]</u></font>
|align = "center"|3
 
|-
|colspan = "3"|<font color="#FF6600">'''Neurotrophin Enhancer'''</font>
 
|-
|align = "center"|MCC-257
|align = "center"|<font color="#0000FF"><u>[http://www.m-pharma.co.jp/cgi-bin/pageview.cgi?pass=/e/develop/situation.html Mitsubishi Pharma]</u></font>
|align = "center"|2
|-
|align = "center"|TRX4
|align = "center"|<font color="#0000FF"><u>[http://www.btgplc.com/PartneredDevelopment/240/TRX4.html BTG]</u></font>
|align = "center"|2
 
|-
|colspan = "3"|<font color="#FF6600">'''Selective inhibitor of fructose-1, 6-bisphosphatase (FBPase)'''</font>
|-
|align = "center"|CS-917
|align = "center"|<u>[http://www.mbasis.com/pipeline/metabolic_disease.html Sankyo,Metabasis]</u>
|align = "center"|2
 
|-
|align = "center"|MB07803
|align = "center"|<font color="#0000FF"><u>[http://www.mbasis.com/pipeline/index.html metabasis, Daiichi Sankyo]</u></font>
|align = "center"|2
|-
|align = "center"|AMG 221
|align = "center"|<font color="#0000FF"><u>[http://wwwext.amgen.com/science/pipe_AMG221.html Amgen, Biovitrum]</u></font>
|align = "center"|1
|-
|-
|align = "center"|IPLEX(Mecasermin rinfabate)
|align = "center"|Glen Allen
|align = "center"|Orphan Drug Status
|-
|bgcolor = "#FFFF99" colspan = "3"|<font color="#FF6600">'''Miscellaneous'''</font>
|-
|align colspan = "center"|&nbsp;|align = "center3"|<font color="#0000FFFF6600"><u>[http://www.metabolex.com/pipeline.html Metabolex]</u>'''Newer Meglitinides'''</font>|align = "center"|1 
|-
|align = "center"|MBX-8025
|align = "center"|<font color="#0000FF"><u>[http://www.metabolex.com/MBX-8025.html Metabolex]</u></font>
|align = "center"|2
 
|-
|align = "center"|Nateglinide with insulin sensitizers
|-
|align colspan = "center3"|&nbsp;|align <font color= "center#FF6600"|&nbsp;|align = "center"|&nbsp;>'''Islet Regeneration Factors'''</font>
|-
|align = "center"|869682
|align = "center"|<font color="#0000FF"><u>[http://clinicaltrials.gov/ct/gui/show/NCT00291356?order=2 Glaxosmithkline]</u></font>
|align = "center"|2
 
|-
|align = "center"|815541
|align = "center"|<font color="#0000FF"><u>[http://www.chartsbank.com/PipelineList.aspx Glaxosmithkline]</u></font>
|align = "center"|1
 
|-
|align = "center"|625019DG770 (beta cell regeneration factor)|align = "center"|<font color="#0000FF"><u>[http://www.chartsbankdevelogen.com/PipelineListen/prod_pipeline.aspx Glaxosmithklinephp?hnav=2&tnav=0 Develogen AG]</u></font>|align = "center"|13
|-
|align = "center"|189075E1 INT (Islet regeneration)|align = "center"|<font color="#0000FF"><u>[http://www.chartsbanktransitiontherapeutics.com/PipelineList.aspx Glaxosmithkline]</u></font>|align = "center"|1 |-|align = "center"|677954|align = "center"|<font color="#0000FF"><u>[http://www.chartsbank.comtechnology/PipelineListindex.aspx Glaxosmithklinephp Transition Therapeutics]</u></font>
|align = "center"|2
|-
|align bgcolor = "center#FFFF99"|PPM-204|align colspan = "center3"|<font color="#0000FFFF6600"><u>[http://www.wyeth.com/research/pipeline Wyeth]</u>'''Miscellaneous'''</font>|align = "center"|2
|-
|align = "center"|CS-011 (Roviglitazone)
|align = "center"|Sankyo
|align = "center"|2
|-
|align = "center"|ACOMPLIA®AMG 837 ( Rimonabant*Potentiates Glucose Dependent Insulin Secretion)|align = "center"|<font color="#0000FF"><u>[http://enwww.sanofi-aventisamgen.com/rdscience/portfolio/p_rd_portfolio_metabopipe_amg837.asp Sanofi Aventishtml Amgen]</u></font>|align = "center"|31
|-
|align = "center"|CS-917MBX 213|align = "center"|Sankyo<font color="#0000FF"><u>[http://www.metabolex.com/pipeline.html Metabolex]</u></font>|align = "center"|21
|-
|align = "center"|R 1499
|align = "center"|<font color="#0000FF"><u>[http://www.chartsbankroche.com/PipelineListpages/downloads/investor/pdf/praesentations/irp050504rdd14.aspx pdf Roche]</u></font>
|align = "center"|1
|-
|align = "center"|R1438
|align = "center"|<font color="#0000FF"><u>[http://www.chartsbankroche.com/PipelineList.aspx Roche]<pages/u><downloads/font>|align = "center"|2 |-|align = "center"|R483|align = "center"|<font color="#0000FF"><u>[http:investor/pdf/www.chartsbank.compraesentations/PipelineListirp050504rdd14.aspx pdf Roche]</u></font>
|align = "center"|2
|-
|align = "center"|R1440
|align = "center"|<font color="#0000FF"><u>[http://www.chartsbankroche.com/PipelineListpages/downloads/investor/pdf/praesentations/irp050504rdd14.aspx pdf Roche]</u></font>
|align = "center"|2
|align = "center"|Neurocrine Biosciences
|align = "center"|2
 
|-
|align = "center"|CS-917
|align = "center"|<font color="#0000FF"><u>[http://www.mbasis.com/pipeline/index.html metabasis, Daiichi Sankyo]</u></font>
|align = "center"|2
 
|-
|align = "center"|MB07803
|align = "center"|<font color="#0000FF"><u>[http://www.mbasis.com/pipeline/index.html metabasis, Daiichi Sankyo]</u></font>
|align = "center"|2
 
|-
|align = "center"|AMPK Project
|align = "center"|<font color="#0000FF"><u>[http://www.mbasis.com/pipeline/index.html metabasis, Daiichi Sankyo]</u></font>
|align = "center"|Discovery
|-
|align = "center"|<font color="#0000FF"><u>[http://www.merck.com/finance/pipeline.swf Merck]</u></font>
|align = "center"|2
 
|-
|align = "center"|Arxxant (ruboxistaurin)
|align = "center"|<font color="#0000FF"><u>[http://investor.lilly.com/pipeline.cfm Eli Lilly]</u></font>
|align = "center"|3
 
|-
|align = "center"|11 B- HSD 1
|align = "center"|<font color="#0000FF"><u>[http://www.biovitrum.com/upload/images/R&D/Projectportfolio_June_2007.pdf Biovitrum, Amgen]</u></font>
|align = "center"|1
 
|-
|align = "center"|Gastrin <nowiki>+</nowiki> Metformin
|align = "center"|<font color="#0000FF"><u>[http://www.transitiontherapeutics.com/technology/index.php Transition Therapeutics]</u></font>
|align = "center"|1
 
|-
|align = "center"|AMG 837
|align = "center"|<font color="#0000FF"><u>[http://wwwext.amgen.com/science/pipe_AMG221.html Amgen]</u></font>
|align = "center"|1
 
|-
|align = "center"|Darbepoetin alfa
|align = "center"|<font color="#0000FF"><u>[http://wwwext.amgen.com/science/pipe_AMG221.html Amgen]</u></font>
|align = "center"|3
 
|-
|align = "center"|Smylin(Amylin analogue)
|align = "center"|<font color="#0000FF"><u>[http://www.amylin.com/pipeline/symlin.cfm Amylin]</u></font>
|align = "center"|4
 
|-
|align = "center"|Exenatide LAR
|align = "center"|<font color="#0000FF"><u>[http://www.amylin.com/pipeline/symlin.cfm Amylin]</u></font>
|align = "center"|2
 
|-
|align = "center"|DG770 (beta cell regeneration factor)
|align = "center"|<font color="#0000FF"><u>[http://www.develogen.com/en/prod_pipeline.php?hnav=2&tnav=0 Develogen AG]</u></font>
|align = "center"|3
 
|-
|align = "center"|E1 INT (Islet regeneration)
|align = "center"|<font color="#0000FF"><u>[http://www.transitiontherapeutics.com/technology/index.php Transition Therapeutics]</u></font>
|align = "center"|2
 
|-
|align = "center"|Mecasermin rinfabate (IPLEX) (IGF 1 and 2)
|align = "center"|<font color="#0000FF"><u>[http://www.fda.gov/cder/drug/InfoSheets/patient/mecasermin_rinfabatePIS.htm Insmed]</u></font>
|align = "center"|Approved in 2005
 
|-
|align = "center"|Orlistat (Xenical) (Lipase inhibitor)
|align = "center"|<font color="#0000FF"><u>[http://www.xenical.com/xen_do_home.asp Roche]</u></font>
|align = "center"|&nbsp;
|-
3.149.251.26
0
edits
Retrieved from "https://www.dolcera.com/wiki/index.php?title=Special:MobileDiff/4473"